In a prespecified secondary analysis of SELECT (17,604 adults with CVD and overweight/obesity, no diabetes), semaglutide cut hsCRP by 37.8% at 104 weeks, including without weight loss, and cut MACE vs placebo across hsCRP subgroups. Higher baseline hsCRP predicted MACE.
Secondary analysisn = 17,604
Plutzky et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis